HomepageTMCI • NASDAQ
add
Treace Medical Concepts Inc
Vorige slotkoers
$ 3,01
Dag-range
$ 2,94 - $ 3,10
Jaar-range
$ 2,56 - $ 10,79
Beurswaarde
189,88 mln. USD
Gem. volume
861,46K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 50,21 mln. | 11,37% |
Bedrijfskosten | 54,38 mln. | 6,08% |
Netto inkomsten | -16,29 mln. | -6,04% |
Netto winstmarge | -32,44 | 4,78% |
Winst per aandeel | -0,22 | 11,36% |
EBITDA | -11,90 mln. | 8,31% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 57,42 mln. | -30,66% |
Totale activa | 196,59 mln. | -7,67% |
Totale passiva | 107,40 mln. | -0,57% |
Totaal aandelenvermogen | 89,19 mln. | — |
Uitstaande aandelen | 63,72 mln. | — |
Koers-boekwaardeverhouding | 2,15 | — |
Rendement op activa | -18,21% | — |
Rendement op kapitaal | -22,42% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -16,29 mln. | -6,04% |
Operationele kasstroom | -9,09 mln. | 23,22% |
Kasstroom uit beleggingen | 8,74 mln. | 51,59% |
Kasstroom uit financiering | -10,00K | -225,00% |
Nettomutatie in liquide middelen | -366,00K | 93,97% |
Vrije kasstroom | -5,94 mln. | 20,86% |
Over
Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.
In March 2021, Treace announced its intent to launch an initial public offering. Trading on the Nasdaq under the ticker symbol “TMCI”, Treace opened its IPO in April 2021. Wikipedia
Opgericht
2014
Website
Werknemers
477
